FIELD: pharmaceutical industry.
SUBSTANCE: invention relates to pharmaceutical industry, in particular to the use of the composition for the prophylactic and/or therapeutic treatment of cystitis. Use of a composition for the prophylactic and/or therapeutic treatment of cystitis, where the composition contains in an effective amount a physiologically compatible salt of chondroitin sulfate in the form of an alkali metal salt at a concentration of 20±2 mg/ml as component (a), where the physiologically compatible salt of chondroitin sulfate has a weight average molecular weight Mw ranging from 10 to 200 kDa, a physiologically compatible hyaluronic acid salt (hyaluronate) in the form of an alkali metal salt at a concentration of 16±1.6 mg/ml as component (b), where the physiologically compatible hyaluronic acid salt has a weight average molecular weight Mw in the range from 10 to 500 kDa, a dihydrogen phosphate/monohydrogen phosphate buffer system as component (c), where the composition contains a dihydrogen phosphate/monohydrogen phosphate buffer system at a total concentration of a dihydrogen phosphate/monohydrogen phosphate buffer system of 1.75±1.65 mg/ml, and where the composition contains a dihydrogen phosphate/monohydrogen phosphate buffer system in the ratio of the mass of dihydrogen phosphate and monohydrogen phosphate in the range from 2:1 to 1:100, at least one physiologically compatible electrolyte as component (d), where the composition contains an electrolyte at a concentration of 8±6 mg/ml, and where the electrolyte is in the form of an alkali metal salt, wherein the composition has a pH in the range of 6.1 to 7.9.
EFFECT: invention has high storage stability and is highly effective in treating cystitis such as interstitial cystitis.
2 cl, 19 tbl, 1 ex
